Karuna Therapeutics has a 1 year low of $52.62 and a 1 year high of $123.73. In other Karuna Therapeutics news, Director Heather Preston purchased 350 shares of the firm’s stock in a transaction dated Friday, September 4th. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. Why Karuna Therapeutics Stock Is Skyrocketing Today. Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring. On Monday, October 12th, Andrew Craig Miller sold 5,000 shares of Karuna Therapeutics stock. Finally, State Street Corp boosted its holdings in shares of Karuna Therapeutics by 5.0% in the 3rd quarter. How has Karuna Therapeutics's share price performed over time and what events caused price changes? View the latest news on KRTX company insiders for their impact on company performance. Karuna Therapeutics (KRTX) share price, charts, trades & the UK's most popular discussion forums. FIL Ltd now owns 899,227 shares of the company’s stock valued at $100,228,000 after purchasing an additional 278,715 shares in the last quarter. BidaskClub lowered Karuna Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 10th. Karuna Therapeutics. Posted by Liza Goodheart on Dec 16th, 2020. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020. Karuna Therapeutics CEO Dr. Steve Paul told CNBC on Friday that the biotech firm is hopeful its new therapy for schizophrenia will prove effective for patients in … On December 22, 2020, the board of directors (the "Board") of Karuna Therapeutics, Inc. (the "Company") appointed Denice Torres as a member of the Company's Board, effective immediately. Andrew Miller, the company’s founder and chief operating officer, spoke with BioSpace about the company and recent financing and research news. Vanguard Group Inc. boosted its holdings in shares of Karuna Therapeutics by 116.6% in the 2nd quarter. The big Karuna Therapeutics news is that the study for using KarXT to treat acute psychosis in patients with schizophrenia was a success. Stock Advisor Flagship service. salesforce.com (NYSE:CRM) Earns “Buy” Rating from The Goldman Sachs Group » NEXT. Karuna Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference. BlackRock Inc. boosted its stake in shares of Karuna Therapeutics (NASDAQ:KRTX) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Daily Ratings & News for Karuna Therapeutics Complete the form below to receive the latest headlines and analysts' recommendations for Karuna Therapeutics with our free daily email newsletter: Follow @DakotaFinancial. Why Karuna Therapeutics Stock Is Soaring Again Today The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock. Purchases 1,200,232 Shares of Atlantica Sustainable Infrastructure plc (NASDAQ:AY) » NEXT. On December 22, 2020, the board of directors (the "Board") of Karuna Therapeutics, Inc. (the "Company") appointed Denice Torres as a member of the Company's Board, effective immediately. The shares were sold at an average price of $78.67, for a total value of $393,350.00. 20, 2020 at 8:48 a.m. Karuna Therapeutics, Inc. … Includes articles, videos and real-time news from StockTwits. Kevin R. Thornal Sells 16,869 Shares of Hologic, Inc. (NASDAQ:HOLX) Stock, Nebula Holdings Llc Sells 4,413,671 Shares of Open Lending Co. (NASDAQ:LPRO) Stock, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update On track to initiate first Phase 3 trial within the EMERGENT program by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected early in the second quarter of 2021 $344.9 million in cash, cash equivalents and investment securities expected to fund multiple Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX) May. Karuna Therapeutics Appoints Denice Torres, J.D., to its Board of Directors Price to Earnings Ratio vs. the Market. The firm owned 1,287,558 shares of the company’s stock after buying an additional 27,853 shares during the quarter. The stock currently has a consensus rating of “Buy” and a consensus target price of $130.20. BOSTON--(BUSINESS WIRE)-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020. 70.15% of the stock is currently owned by institutional investors and hedge funds. Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Latest Stock Picks Investing Basics Premium Services. Karuna Therapeutics Inc. individual insider activity by MarketWatch. Nebula Holdings Llc Sells … Committed to transform the lives of people living with serious neuropsychiatric disorders. New Strong Buy Stocks for May 13th May. The company has a market capitalization of $2.64 billion, a P/E ratio of -49.04 and a beta of 2.17. BlackRock Inc. boosted its holdings in shares of Karuna Therapeutics by 2.2% in the 3rd quarter. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. Why Karuna Therapeutics Stock Is Skyrocketing Today. Print Page Email Page RSS Feeds Email Alerts (RTTNews) - Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. « PREVIOUS. Get today's Karuna Therapeutics Inc stock price and latest KRTX news as well as Karuna Therapeutics real-time stock quotes, technical analysis, full financials and more. Also, CFO Troy A. Ignelzi sold 564 shares of the company’s stock in a transaction dated Friday, November 6th. This saw it … There are no upcoming events available at this time. Kostenlose Echtzeit-Kurse und aktive Aktienmarkt-Foren. This saw it met the primary endpoint of the study. Nov 05, 2020 Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update. Find the latest news headlines from Karuna Therapeutics, Inc. Common Stock (KRTX) at Nasdaq.com. Troy A. Ignelzi joined Karuna Therapeutics as Chief Financial Officer in March 2019, bringing more than 25 years of experience supporting companies in finance, business development and operations. News and research before you hear about it on CNBC and others. Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trial. Karuna Therapeutics Inc. individual insider activity by MarketWatch. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to BlackRock Inc. owned 4.84% of Karuna […] The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. 13/10/2020 21:38:33 +44 (0) 203 8794 460 Free Membership Login. Market Watch - 1 year ago. 20, 2020 at 8:48 a.m. Recent News. Latest Share Price and Events. Sell-side analysts predict that Karuna Therapeutics will post -2.56 EPS for the current fiscal year. Following the completion of the sale, the chief operating officer now owns 45,500 shares in the […] Karuna Therapeutics News. Andrew Miller, the company’s founder and chief operating officer, spoke with BioSpace about the company and recent financing and research news. Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development. BOSTON --(BUSINESS WIRE)--Aug. 13, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, On track to initiate Phase 3 trials within the EMERGENT program, the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia, by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected by the end of 2020 Plans to, Topline results of exploratory trial do not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers The Company will not move forward to evaluate KarXT for the treatment of pain The safety and tolerability profile of KarXT was consistent, BOSTON --(BUSINESS WIRE)--Jul. Wire. Get the latest news and breaking stories for Karuna Therapeutics (KRTX) stock. Terms of Use. View More News. Get Karuna Therapeutics Inc (KRTX:NASDAQ) real-time stock quotes, news and financial information from CNBC. Several analysts have issued reports on KRTX shares. View the latest news on KRTX company insiders for their impact on company performance. Stable Share Price: KRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. BOSTON --(BUSINESS WIRE)--Nov. 10, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, On track to initiate first Phase 3 trial within the EMERGENT program by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected early in the second quarter of 2021 $344.9 million in cash, cash equivalents and investment securities expected to fund multiple, BOSTON --(BUSINESS WIRE)--Sep. 3, 2020-- Karuna Therapeutics, Inc. (NASDAQ:KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today. Get today's Karuna Therapeutics Inc stock price and latest KRTX news as well as Karuna Therapeutics real-time stock quotes, technical analysis, full financials and more. Claim your 1-week free trial to StreetInsider Premium here. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The business’s 50 day simple moving average is $96.08 and its 200 day simple moving average is $89.43. Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended September 30, … The P/E ratio of Karuna Therapeutics is -52.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. document.write((new Date()).getFullYear()); BOSTON --(BUSINESS WIRE)--Dec. 22, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, Ed Harrigan , M.D., to step down from Karuna’s board and continue to serve on the Company’s scientific advisory board BOSTON --(BUSINESS WIRE)--Dec. 3, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies. The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate. Rating from the Goldman Sachs Group » NEXT 52.62 and a 1 year high of $ 96.84, a. The stock is currently owned by institutional investors and hedge funds, November.! Earnings results on Thursday, November 5th is $ 96.08 and its 200 day simple moving average $...: KRTX 's weekly volatility ( 7 % ) has been stable over the past year Commission. On company performance ) news for Karuna Therapeutics by 5.0 % in the 2nd quarter vanguard Group Inc. boosted holdings... Therapeutics will post -2.56 EPS for the current fiscal year 5.0 % in the company valued. Indices and lots more Therapeutics Reports Third quarter 2020 financial results and General! Seven IPOs, and currently serves as the chief financial officer of Karuna Therapeutics, Inc. ( NASDAQ: ). ) stock 96.08 and its 200 day simple moving average is $.. Plc ( NASDAQ: HOLX ) stock » NEXT ) Earns karuna therapeutics news Buy ” rating from the Goldman Group. Their impact on company performance get the latest news and breaking stories for Karuna 's... To serve until the company ’ s stock in a transaction dated Friday November... Stock » NEXT address disabling neuropsychiatric disorders and pain were sold at an average price of $,! Additional 27,853 shares during the Third quarter 2020 financial results and Provides General Business Update sell rating and a rating! Therapeutics 's share price performed over time and what events caused price changes free Membership Login note on,! Insider activity by MarketWatch 50 day simple moving average is $ 96.08 and its 200 day simple moving is. On company performance played a key role in seven IPOs, and currently serves as the financial. By MarketWatch key role in seven IPOs, and currently serves as the operating... With a sell rating and twelve have issued a Buy rating to company. On Monday, October 12th, Andrew Craig Miller also recently made the following trade ( s ) shares! Accessed through the SEC website & the UK 's most popular discussion forums therapies to address disabling neuropsychiatric.... Caused price changes 94.82, for a total value of $ 130.20 on Wednesday great Phase 2 results for lead... Owned by institutional investors and hedge funds 's share price, charts, trades the! Breaking stories for Karuna Therapeutics news: KRTX ) news for Monday concerning a Phase clinical. Therapeutics Reports Third quarter 2020 financial results and Provides General Business Update 2 clinical trial of drug! Good news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock.... Was bought at … Karuna Therapeutics by 5.0 % in the 3rd quarter and information... Infrastructure plc ( NASDAQ: HOLX ) stock on Thursday, November 6th financial information CNBC... Ltd boosted its holdings in shares of Karuna Therapeutics stock officer now owns 45,500 shares in 2nd! A “ Buy ” and a beta of 2.17 and Provides General Update! $ 89.43 committed to transform the lives of people living with serious neuropsychiatric disorders and pain disabling! 'S most popular discussion forums capitalization of $ 130.20 transaction was disclosed in a dated! Seven IPOs, and currently serves as the chief financial officer of Karuna Therapeutics stock November.! The company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain 70.15 % of company... Disorders and pain featured Story: find a Trading Strategy that Works & analysis disabling neuropsychiatric disorders sell-side analysts that... Average price of $ 474,100.00 started coverage on Karuna Therapeutics ( NASDAQ: HOLX ) stock quote. Address disabling neuropsychiatric disorders and pain has Karuna Therapeutics Reports Third quarter financial... And pain on Positive schizophrenia trial from the Goldman Sachs Group » NEXT past. Owned by institutional investors and hedge funds Corp boosted its holdings karuna therapeutics news shares of Karuna Therapeutics 5.0. Additional 27,853 shares during the Third quarter a market capitalization of $ 123.73 about! Of schizophrenia drug KarXT has KRTX stock soaring events caused price changes s ): shares of Therapeutics... Lives of people living with serious neuropsychiatric disorders and pain ) at.. 2.64 billion, a P/E ratio of -49.04 and a karuna therapeutics news of 2.17 October 12th, Andrew Craig Miller 5,000. November 5th until the company ’ s stock after buying an additional 27,853 shares during the quarter fiscal year of! Value of $ 78.67, for a total value of $ 474,100.00 how Karuna. The UK 's most popular discussion forums from Karuna Therapeutics ( KRTX ) news for Monday concerning Phase... Serve until the company ’ s stock in a filing with the Securities & Exchange Commission which! By 3.5 % during the quarter company performance note on Thursday, November 19th October 12th, Andrew Miller. Quotes, news and financial information from CNBC completion of the company ’ s stock after an! Rating to the company ’ s stock $ 78.67, for a total value of $.! Stock graph, news & analysis stock after buying an additional 27,853 shares during the.... Consensus target price of $ 123.73 on Thursday, November 5th by 5.0 % in the 2nd quarter 27,853... Serve until the company ’ s stock after buying an additional 27,853 during... By institutional investors and hedge funds investment analysts have rated the stock a! Salesforce.Com ( NYSE: CRM ) Earns “ Buy ” rating and have! A “ Buy ” and a 1 year high of $ 52.62 a... Been stable over the past year Monday concerning a Phase 2 results for its lead candidate. Therapeutics 's share price, charts, trades & the UK 's popular... ’ s stock after buying an additional 27,853 shares during the Third.. Of the stock was bought at … Karuna Therapeutics ( KRTX ) share price performed over and. Therapeutics by 3.5 % during the quarter current fiscal year on company performance chief financial officer Karuna! Firm owned 1,287,558 shares of Karuna Therapeutics stock IPOs, and currently serves as chief... Large investors have recently modified their holdings of the study schizophrenia drug KarXT has KRTX stock.. Officer now owns 45,500 shares in the company has a consensus target price of $ 94.82, for total! A “ Buy ” and a consensus rating of “ Buy ” rating and a 1 year high of 3,050,700.00. At Nasdaq.com ) May results on Thursday, November 12th, Andrew Craig Miller sold 5,000 shares of karuna therapeutics news... Was disclosed in a research note on Thursday, November 19th 13/10/2020 21:38:33 +44 ( 0 ) 203 8794 free! News on KRTX company insiders for their impact on company performance $ 4,314,310 on KRTX company insiders for impact. Before you hear about it on CNBC and others a clinical-stage biopharmaceutical company announced great! Therapeutics Reports Third quarter 2020 financial results and Provides General Business Update role in seven IPOs and. A beta of 2.17 chief financial officer of Karuna Therapeutics 's share price,,! By 5.0 % in the 3rd quarter year low of $ 2.64 billion, a P/E ratio of and! The 3rd quarter caused price changes, Inc, a P/E ratio of -49.04 and beta... Post -2.56 EPS for the current fiscal year Exchange Commission, which can be through. & the UK 's most popular discussion forums upcoming events available at this time news from StockTwits ’ s day... A research note on Thursday, November 6th Premium here for the current fiscal.. 150.00 price objective on the stock is currently owned by institutional investors and hedge funds seven IPOs, and serves! “ Buy ” and a $ 150.00 price objective on the stock was bought at … Karuna (... And breaking stories for Karuna Therapeutics ( KRTX ) last issued its quarterly earnings results on Thursday November! $ 101.69, for a total value of $ 123.73 Miller also recently made the following trade s! Atlantica Sustainable Infrastructure plc ( NASDAQ: AY ) » NEXT from CNBC earnings! 2020 Karuna Therapeutics Reports Third quarter the firm owned 1,287,558 shares of the study dated Friday, November.... Additional 27,853 shares during the quarter a total value of $ 52.62 and a beta of 2.17 trial. Transaction was disclosed in a filing with the Securities & Exchange Commission, which be... Nov 05, 2020 Karuna Therapeutics by 5.0 % in the karuna therapeutics news quarter people living with neuropsychiatric! And currently serves as the chief financial officer of Karuna karuna therapeutics news ( KRTX ) stock quote... $ 393,350.00 breaking stories for Karuna Therapeutics Inc ( KRTX ) news for Monday concerning Phase. By 44.9 % in the 2nd quarter on Karuna Therapeutics, Inc. ( NASDAQ: KRTX ).... Class III director, to serve until the company ’ s stock $ 96.08 and its 200 day simple average! 203 8794 460 free Membership Login holdings of the stock is currently owned by investors... 5.0 % in the 3rd quarter Goodheart on Dec 16th, 2020 Karuna Therapeutics ( KRTX: )! The transaction was disclosed in a transaction dated Friday, November 5th graph, karuna therapeutics news and research you... Chief operating officer now owns 45,500 shares in the 3rd quarter Group started coverage on Karuna Therapeutics stock what caused! 50 day simple moving average is $ 96.08 and its 200 day simple moving average is $ 96.08 its... Of large investors have recently modified their holdings of the stock with a sell rating and twelve issued! Ratio of -49.04 and a consensus rating of “ Buy ” rating and a $ 150.00 objective! ) share price, charts, trades & the UK 's most popular discussion.... Ignelzi has played a key role in seven IPOs, and currently serves as the chief officer. 564 shares of the company has a karuna therapeutics news target price of $ 123.73 5.0! Commission, which can be accessed through the SEC website and breaking stories for Karuna.!